Open AccessMechanisms of neuroprotective action of incretin mimetics
Author(s) -
Т. Д. Власов,
А. В. Симаненкова,
С. В. Дора,
Evgeniy Vladimirovich Shlyakhto
Publication year - 2016
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm7192
Subject(s) - neuroprotection , incretin , medicine , pharmacology , diabetes mellitus , receptor , glucagon like peptide 1 , type 2 diabetes mellitus , neuroscience , bioinformatics , type 2 diabetes , endocrinology , biology
Recently, on the pharmacological market, new drugs from the class of incretin mimetics, or glucagon-like peptide-1 (GLP-1) receptor agonists, which have proven their high effectiveness in type 2 diabetes mellitus therapy, have appeared. At present, much attention has been paid to the pleotropic effects of incretin mimetics. In a number of both experimental and clinical studies, cardioprotective effects of this medication group have been demonstrated. The present review elucidates existing data about neuroprotective effects of GLP-1 receptor agonists in brain ischaemia and in nonischaemic nervous system diseases such as diabetic neuropathy and neurodegenerative disorders. The possible mechanisms for these effects, which appear to be primarily antioxidant effects, anti-inflammatory effects, antiapoptotic effects and an increase in neurons differentiation, are discussed.